May 2nd 2025
Collagen structure and vessel density vary by photoaging type, highlighting the value of multimodal imaging in guiding individualized skin care strategies.
Clinical Consultations™: Optimizing Treatment Outcomes for Patients with Generalized Pustular Psoriasis
View More
Revolutionizing Atopic Dermatitis (RAD) Conference 2025
June 6-7, 2025
Register Now!
Cases and Conversations™: Biologic Matchmaking in Psoriasis – Finding the Right Therapy for the Right Patient
July 26, 2025
Register Now!
Advances in™ Atopic Dermatitis: Addressing Unmet Needs in Patients With Skin of Color
View More
Clinical Consultations™: Guiding Patients with Genital Psoriasis Toward Relief Through a Multidisciplinary Approach
View More
Patient, Provider & Caregiver Connection™: Understanding the Patient Journey to Provide Personalized Care for Generalized Pustular Psoriasis
View More
Cases and Conversations™: Applying Practice Techniques to Optimize Diagnosis and Treatment Strategies in Generalized Pustular Psoriasis
View More
Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice
View More
‘REEL’ Time Patient Counseling™: Fostering Effective Conversations in Practice to Create a Visible Impact for Patients Living with Genital Psoriasis
View More
Dermalorian™ Webinar: Shedding Light on Patient-Reported Outcomes to Assess Disease Severity in Patients With Atopic Dermatitis
View More
Where Do Biologics Fit Into the Management of Moderate-to-Severe Atopic Dermatitis?
View More
Expert Illustrations & Commentaries™: Exploring Novel Therapeutic Targets in Acne Management
View More
Burst CME: Targeted Therapy for Optimal Psoriasis Management
View More
New generation HA-based filler improves results
October 1st 2006National report - Results of a pivotal study evaluating a new generation hyaluronic acid (HA)-based gel filler (Juv?derm, Allergan) for correction of nasolabial folds show that all three formulations of the injectable product provide significantly greater and longer-lasting improvement than crosslinked bovine collagen (Zyplast, Allergan) reports Leslie Baumann, M.D.
Phase 4 study reaffirms safety of low-dose acitretin
September 1st 2006Results of a phase 4, open-label, multicenter study indicate that low-dose acitretin (Soriatane, Connetics) in moderate to severe psoriasis patients provides efficacy as monotherapy by 24 weeks, but requires patience, said Gerald G. Krueger, M.D., at the American Academy of Dermatology's Academy '06.